NasdaqGM - Delayed Quote USD
NewAmsterdam Pharma Company N.V. (NAMS)
At close: November 6 at 4:00 PM EST
After hours: November 6 at 4:01 PM EST
Insider Purchases Last 6 Months
Shares | Transactions | |
---|---|---|
Purchases | 56,104 | 4 |
Sales | 45,000 | 1 |
Net Shares Purchased (Sold) | 11,104 | 5 |
Total Insider Shares Held | 234.94k | -- |
% Net Shares Purchased (Sold) | 5.00% | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
Shares | |
---|---|
Net Shares Purchased (Sold) | -- |
% Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
Insider | Transaction | Type | Value | Date |
---|---|---|---|---|
KOOIJ LOUISE FREDERIKA Officer | Sale at price 15.72 per share. | Direct | 707,400 | Oct 1, 2024 |
KOOIJ LOUISE FREDERIKA Officer | -- | Direct | -- | Sep 27, 2024 |
AUDET JULIETTE BERANGERE Officer | Purchase at price 15.70 per share. | Direct | 17,333 | Sep 26, 2024 |
DAVIDSON MICHAEL H Chief Executive Officer | Purchase at price 16.27 per share. | Direct | 81,350 | Aug 20, 2024 |
DAVIDSON MICHAEL H Chief Executive Officer | Purchase at price 17.26 per share. | Direct | 86,308 | Jun 20, 2024 |
TOPPER JAMES N Director | Purchase at price 21.50 per share. | Indirect | 181,224 | Mar 26, 2024 |
KASTELEIN JOHANNES JACOB PIETER M.D., PH.D. Officer and Director | -- | Indirect | -- | Mar 26, 2024 |
KASTELEIN JOHANNES JACOB PIETER M.D., PH.D. Officer and Director | Sale at price 21.50 per share. | Indirect | 4,095,234 | Mar 26, 2024 |
LANGE LOUIS G M.D., PH.D. Director | Purchase at price 19.00 per share. | Indirect | 95,000 | Feb 13, 2024 |
BIGHAM MICHAEL F Director | Conversion of Exercise of derivative security at price 9.87 per share. | Direct | 296,100 | Nov 22, 2022 |
BALTERA ROBERT F JR. Director | Conversion of Exercise of derivative security at price 9.87 per share. | Direct | 296,100 | Nov 22, 2022 |
POLU KRISHNA R Director | Conversion of Exercise of derivative security at price 9.87 per share. | Direct | 296,100 | Nov 22, 2022 |
TOPPER DAVID JOSEPH Chief Financial Officer | Conversion of Exercise of derivative security at price 9.87 per share. | Direct | 296,100 | Nov 22, 2022 |
Related Tickers
SYRE Spyre Therapeutics, Inc.
37.48
+4.34%
MRUS Merus N.V.
53.13
+2.67%
CGEM Cullinan Therapeutics, Inc.
16.48
+3.13%
ATXS Astria Therapeutics, Inc.
11.87
+3.13%
TYRA Tyra Biosciences, Inc.
17.12
+2.15%
BCYC Bicycle Therapeutics plc
23.64
+0.55%
DYN Dyne Therapeutics, Inc.
29.81
+4.16%
XENE Xenon Pharmaceuticals Inc.
44.94
+3.72%
IRON Disc Medicine, Inc.
64.80
+0.04%
NMRA Neumora Therapeutics, Inc.
12.71
+6.72%